CELLTOP: A Phase I Clinical Trial of Autologous Adipose Derived Mesenchymal Stem Cells in the Treatment of Paralysis due to Traumatic Spinal Cord Injury

This clinical trial investigates whether adipose-derived (fat tissue-derived) mesenchymal stem cells can be safely administered into the cerebrospinal fluid of patients with traumatic spinal cord injury and what the effects this may have on functional improvement, activities of daily living, and quality of life. If successful, this study may create a viable clinical option for spinal cord injury patients by establishing feasibility and safety data for patients who do not have many treatment options.

Mayo Clinic
Mohamad Bydon, MD